ProCE Banner Activity

Addressing the Medical Need in CLL: Selecting First-line Therapy

Slideset Download
Download this slideset from Ian W. Flinn, MD, PhD and Susan M. O’Brien, MD for the most recent data selecting first-line therapy for patients with CLL, including differences in treatment selection for patients with or without del(17p) or TP53 mutations.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Susan M. O Brien

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Faculty Disclosure

Primary Author

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas